These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 31882668)

  • 1. Restoration of liver sinusoidal cell phenotypes by statins improves portal hypertension and histology in rats with NASH.
    Bravo M; Raurell I; Hide D; Fernández-Iglesias A; Gil M; Barberá A; Salcedo MT; Augustin S; Genescà J; Martell M
    Sci Rep; 2019 Dec; 9(1):20183. PubMed ID: 31882668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergic effect of atorvastatin and ambrisentan on sinusoidal and hemodynamic alterations in a rat model of NASH.
    Bravo M; Raurell I; Barberá A; Hide D; Gil M; Estrella F; Salcedo MT; Augustin S; Genescà J; Martell M
    Dis Model Mech; 2021 May; 14(5):. PubMed ID: 34014280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Restoration of a healthy intestinal microbiota normalizes portal hypertension in a rat model of nonalcoholic steatohepatitis.
    García-Lezana T; Raurell I; Bravo M; Torres-Arauz M; Salcedo MT; Santiago A; Schoenenberger A; Manichanh C; Genescà J; Martell M; Augustin S
    Hepatology; 2018 Apr; 67(4):1485-1498. PubMed ID: 29113028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Steatosis as main determinant of portal hypertension through a restriction of hepatic sinusoidal area in a dietary rat nash model.
    Barberá A; Raurell I; García-Lezana T; Torres-Arauz M; Bravo M; Hide D; Gil M; Salcedo MT; Genescà J; Martell M; Augustin S
    Liver Int; 2020 Nov; 40(11):2732-2743. PubMed ID: 32770818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A defect in endothelial autophagy occurs in patients with non-alcoholic steatohepatitis and promotes inflammation and fibrosis.
    Hammoutene A; Biquard L; Lasselin J; Kheloufi M; Tanguy M; Vion AC; Mérian J; Colnot N; Loyer X; Tedgui A; Codogno P; Lotersztajn S; Paradis V; Boulanger CM; Rautou PE
    J Hepatol; 2020 Mar; 72(3):528-538. PubMed ID: 31726115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liver sinusoidal endothelial cell expressed vascular cell adhesion molecule 1 promotes liver fibrosis.
    Guo Q; Furuta K; Islam S; Caporarello N; Kostallari E; Dielis K; Tschumperlin DJ; Hirsova P; Ibrahim SH
    Front Immunol; 2022; 13():983255. PubMed ID: 36091042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endothelial group IVA phospholipase A
    Kawashita E; Ozaki T; Ishihara K; Kashiwada C; Akiba S
    Life Sci; 2022 Apr; 294():120355. PubMed ID: 35093339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aerobic exercise training in the treatment of non-alcoholic fatty liver disease related fibrosis.
    Linden MA; Sheldon RD; Meers GM; Ortinau LC; Morris EM; Booth FW; Kanaley JA; Vieira-Potter VJ; Sowers JR; Ibdah JA; Thyfault JP; Laughlin MH; Rector RS
    J Physiol; 2016 Sep; 594(18):5271-84. PubMed ID: 27104887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease.
    Boyer-Diaz Z; Aristu-Zabalza P; Andrés-Rozas M; Robert C; Ortega-Ribera M; Fernández-Iglesias A; Broqua P; Junien JL; Wettstein G; Bosch J; Gracia-Sancho J
    J Hepatol; 2021 May; 74(5):1188-1199. PubMed ID: 33278455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis - Effects of a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist and a glucagon-like peptide-1 analogue.
    Daniels SJ; Leeming DJ; Detlefsen S; Bruun MF; Hjuler ST; Henriksen K; Hein P; Karsdal MA; Brockbank S; Cruwys S
    Biomed Pharmacother; 2019 Mar; 111():926-933. PubMed ID: 30841472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simvastatin Prevents Progression of Acute on Chronic Liver Failure in Rats With Cirrhosis and Portal Hypertension.
    Tripathi DM; Vilaseca M; Lafoz E; Garcia-Calderó H; Viegas Haute G; Fernández-Iglesias A; Rodrigues de Oliveira J; García-Pagán JC; Bosch J; Gracia-Sancho J
    Gastroenterology; 2018 Nov; 155(5):1564-1577. PubMed ID: 30055171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
    Eslami L; Merat S; Malekzadeh R; Nasseri-Moghaddam S; Aramin H
    Cochrane Database Syst Rev; 2013 Dec; (12):CD008623. PubMed ID: 24374462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tofogliflozin Delays Portal Hypertension and Hepatic Fibrosis by Inhibiting Sinusoidal Capillarization in Cirrhotic Rats.
    Asada S; Kaji K; Nishimura N; Koizumi A; Matsuda T; Tanaka M; Yorioka N; Sato S; Kitagawa K; Namisaki T; Akahane T; Yoshiji H
    Cells; 2024 Mar; 13(6):. PubMed ID: 38534382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk.
    Athyros VG; Boutari C; Stavropoulos K; Anagnostis P; Imprialos KP; Doumas M; Karagiannis A
    Curr Vasc Pharmacol; 2018; 16(3):246-253. PubMed ID: 28676019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of Insulin-PI3K/Akt-p70S6K Pathway in Hepatic Stellate Cells Contributes to Fibrosis in Nonalcoholic Steatohepatitis.
    Cai CX; Buddha H; Castelino-Prabhu S; Zhang Z; Britton RS; Bacon BR; Neuschwander-Tetri BA
    Dig Dis Sci; 2017 Apr; 62(4):968-978. PubMed ID: 28194671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs.
    Caldwell S
    Clin Mol Hepatol; 2017 Jun; 23(2):103-108. PubMed ID: 28494529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New cellular and molecular targets for the treatment of portal hypertension.
    Gracia-Sancho J; Maeso-Díaz R; Fernández-Iglesias A; Navarro-Zornoza M; Bosch J
    Hepatol Int; 2015 Apr; 9(2):183-91. PubMed ID: 25788198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Depletion of Activated Hepatic Stellate Cells and Capillarized Liver Sinusoidal Endothelial Cells Using a Rationally Designed Protein for Nonalcoholic Steatohepatitis and Alcoholic Hepatitis Treatment.
    Mishra F; Yuan Y; Yang JJ; Li B; Chan P; Liu Z
    Int J Mol Sci; 2024 Jul; 25(13):. PubMed ID: 39000553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Role of Statins in the Management of Nonalcoholic Fatty Liver Disease.
    Doumas M; Imprialos K; Dimakopoulou A; Stavropoulos K; Binas A; Athyros VG
    Curr Pharm Des; 2018; 24(38):4587-4592. PubMed ID: 30652643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
    Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
    Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.